How to Apply to Daewoong Pharmaceutical

18 min read Last updated April 20, 2026 6 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • Daewoong Pharmaceutical (대웅제약, KOSPI: 069620) is a Seoul-headquartered Korean big pharma with roughly 2,000 direct employees, founded in 1945 and operated under the founder's family with Yoon Jae-seung as Chairman.
  • The company runs a custom in-house recruiting portal at recruit.daewoong.co.kr — not Greenhouse, Workday, or any Western ATS — with full Korean and partial English interfaces and a Korean-mobile-number-based notification model.
  • Hiring runs on two tracks: shin-ip gong-chae (신입 공채) annual new-graduate cohorts with structured calendars and group assessment days, and gyeong-lyeok-jik (경력직) experienced-hire requisitions posted on a rolling basis.
  • The ja-so-seo (자기소개서) Korean-language self-introduction essay is the single most important written document in any application; each prompt has a hard character limit, and recycled essays are easy to spot and immediately downgraded.
  • Daewoong's three franchise pillars in 2026 are Nabota (botulinum toxin, partnered globally with Evolus as Jeuveau and Nuceiva), Fexuclue (P-CAB for GERD with a 2024 China launch via Yangtze River Pharmaceutical), and Anpec (anti-cholesterol).
  • The 2019–2024 Medytox litigation over the Nabota strain provenance was substantially resolved via a 2021 settlement (~$13.5M plus royalty arrangements) and is operationally behind the company; candidates should engage with it factually and briefly if asked.
  • Korean primary at HQ, English working-language for global business unit and overseas-partner-facing roles; bilingual capability is a baseline expectation for any global-track role.
  • Daewoong competes for top Korean pharma talent against Hanmi, Yuhan, Chong Kun Dang, GC Cell, and (for biologics) Samsung Biologics and Celltrion; lateral movement within this set is common and well understood by interviewers.
  • The interview process for gong-chae includes document screen, in-jeok-seong-geom-sa aptitude test, structured first-round panel with PT element, and a formal executive final round; total timeline runs 8–12 weeks.
  • The Daewoong Group structure (Daewoong Co. as holding parent, Daewoong Pharmaceutical as the listed operating company, Daewoong Bio as the CDMO arm, Hanall Biopharma as a Kosdaq-listed minority-held affiliate) shapes career mobility; understanding this structure signals serious preparation.

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. (대웅제약, KOSPI: 069620) is one of the five anchor companies of the modern Korean pharmaceutical industry, headquartered in Seoul with manufacturing and R&D infrastructure across Hyangnam (Hwaseong), Osong, and Yongin. Founded in 1945 and operated for the better part of three generations under the founder's family — Yoon Jae-seung serves as Chairman and remains the ownership and strategic anchor of the broader Daewoong Group conglomerate — the company employs roughly 2,000 people directly, with several thousand more across its sister entities, including Daewoong Bio (CDMO and APIs), Hanall Biopharma (a Daewoong-affiliated Kosdaq biotech in which the group holds a meaningful minority position), and a network of Daewoong-branded affiliates spanning logistics, animal health, and bioventures. Daewoong's commercial identity in 2026 is defined by three franchises. Nabota (나보타), the company's botulinum toxin type A product, is the global revenue engine: out-licensed to Evolus in the United States as Jeuveau and to Nuceiva in Europe and Canada, the franchise has scaled into an aesthetics and therapeutics product line that contributes a meaningful share of consolidated operating profit and gives Daewoong a globally recognized brand in a category historically dominated by Allergan's Botox. Fexuclue (펙수클루, fexuprazan), Daewoong's in-house P-CAB (potassium-competitive acid blocker) for gastroesophageal reflux disease and related acid-suppression indications, is the company's strategic bet on becoming a globally relevant originator: it launched in Korea in 2022, secured a major China commercialization partnership with Yangtze River Pharmaceutical for a 2024 launch, and is the centerpiece of the company's out-licensing pipeline across emerging markets. Anpec (안펙), an anti-cholesterol product, anchors the domestic chronic-disease portfolio alongside a long tail of in-licensed and co-promoted brands. Beneath those franchises sits a classical Korean big-pharma operating model: a large domestic sales force calling on hospitals, clinics, and pharmacies; a substantial CDMO and contract manufacturing arm through Daewoong Bio; an in-house R&D pipeline focused on metabolic disease, autoimmune indications, oncology, and antifibrotics; and a growing global business unit that manages out-licensing, regional joint ventures, and direct subsidiaries in markets including China, Indonesia, Vietnam, India, the United States, and parts of the Middle East. Daewoong has been one of the more aggressive Korean pharma companies in pushing for genuinely global product registrations rather than relying solely on Korean and adjacent-market revenue, and that strategic posture is visible in how it hires. The company is publicly traded on the KOSPI under ticker 069620, reports quarterly results in Korean and English, and maintains a corporate governance structure typical of Korean chaebol-affiliated pharma — a founding-family-anchored holding structure (Daewoong Co., Ltd., the holding company, sits above Daewoong Pharmaceutical and the affiliated entities), professional management at the operating-company level, and a CEO who reports into both the Chairman and the board. Investors and candidates should understand that strategic decisions on major capital allocation, M&A, and global partnerships ultimately route through the Chairman and the holding company, while day-to-day operating decisions are handled by the Daewoong Pharmaceutical CEO and executive team. The most candid context any candidate should walk in with is the Medytox litigation arc that defined Daewoong's global narrative from roughly 2019 through 2024. Medytox, a Korean competitor, alleged that Daewoong had improperly obtained the bacterial strain underlying Nabota, leading to multi-jurisdictional civil and trade actions including an International Trade Commission proceeding in the United States. The dispute was substantially resolved in 2021 through a settlement involving Daewoong's U.S. partner Evolus, with a reported payment in the range of $13.5 million plus ongoing royalty arrangements, and remaining ancillary matters wound down through 2024. The company today treats the matter as resolved and operationally behind it, but the episode shaped how Daewoong communicates about IP provenance, product origin, and partner due diligence — and you should expect that anyone interviewing for a regulatory, legal, business development, or quality role will be conversant with the public record. Treating the litigation as a normal, resolved part of the corporate history (rather than a taboo subject) is the right posture for candidates. For 2026, hiring at Daewoong is concentrated in three areas: the global business unit and out-licensing organization (driven by Fexuclue's international rollout and ongoing Nabota market expansion); R&D, particularly in early development, translational science, and clinical operations supporting the in-house pipeline; and the manufacturing and quality functions tied to Hyangnam, Osong, and Daewoong Bio's CDMO buildout. Domestic sales hiring is steady but more cyclical, and shared-services hiring (finance, IT, HR, legal) follows the traditional Korean shin-ip gong-chae (신입 공채, new-graduate cohort) calendar with periodic experienced-hire (gyeong-lyeok-jik, 경력직) postings for specialist roles.

Application Process

  1. 1
    Start at the official Daewoong Pharmaceutical recruiting portal at recruit

    Start at the official Daewoong Pharmaceutical recruiting portal at recruit.daewoong.co.kr, which is the canonical source for all open requisitions. The corporate site daewoong.co.kr links to the same portal under the 채용 (Recruiting) navigation. Both Korean and English interfaces are available, but the English version typically lists a subset of roles oriented toward global business and overseas subsidiaries; Korean-language candidates should default to the Korean portal for full coverage.

  2. 2
    Identify whether the role is part of a shin-ip gong-chae (신입 공채, structured new-

    Identify whether the role is part of a shin-ip gong-chae (신입 공채, structured new-graduate cohort hire), a gyeong-lyeok-jik (경력직, experienced-hire requisition), or an intern/contract posting. Gong-chae cycles run on a published calendar — typically one major cohort per year with a smaller secondary intake — and have hard application deadlines, group assessment days, and a fixed start date. Experienced-hire roles are posted on a rolling basis and follow a more conventional applicant-by-applicant flow.

  3. 3
    Create an account on the recruit

    Create an account on the recruit.daewoong.co.kr portal. The system requires a Korean mobile phone number for verification by default; international applicants without a Korean number should look for the global-roles section or apply through the overseas subsidiary's local channel (LinkedIn or country-specific career pages for the U.S., China, Indonesia, Vietnam, and India operations). Account credentials persist across application cycles, so candidates re-applying in subsequent gong-chae rounds reuse the same profile.

  4. 4
    Complete the structured application form

    Complete the structured application form. This is a Korean-style application, which means in addition to standard biographical fields you will provide academic transcripts, a list of certifications (including national qualifications such as 약사 면허 for pharmacists, 위해요소중점관리기준 (HACCP) credentials for relevant manufacturing roles, language proficiency scores like TOEIC, OPIc, or TEPS for English and HSK or JLPT where applicable), military service status for male applicants, and detailed prior employment history.

  5. 5
    Write the ja-so-seo (자기소개서, self-introduction essay), which is the single most i

    Write the ja-so-seo (자기소개서, self-introduction essay), which is the single most important written element of any Korean gong-chae application. Daewoong's ja-so-seo prompts typically include four to five questions covering motivation for joining Daewoong, a story of overcoming a significant challenge, a description of teamwork or leadership experience, a vision statement for your career trajectory, and a question tied to Daewoong's stated values (생명존중, 정직, 도전 — respect for life, integrity, challenge). Each question typically has a strict character limit of 500 to 1,000 Korean characters; exceeding the limit truncates your answer.

  6. 6
    Submit the application before the published deadline

    Submit the application before the published deadline. Gong-chae deadlines are absolute and the portal closes at the stated time (typically 23:59 KST on the final day). Late submissions are not accepted under any circumstances. Save drafts as you work — the portal supports save-and-resume but has been known to time out long sessions, and recovering a lost ja-so-seo draft is one of the most common candidate frustrations.

  7. 7
    Wait for the document-screening result (서류전형 발표)

    Wait for the document-screening result (서류전형 발표). For gong-chae cycles this is announced on a published date, usually two to four weeks after the deadline; for experienced-hire roles it varies from one week to over a month depending on requisition activity. Notification is delivered through the portal and via SMS to your registered Korean number. Candidates who pass the document screen are invited to the next stage; those who do not are notified with a brief standard message.

  8. 8
    For gong-chae candidates, the next stage is typically the in-jeok-seong-geom-sa

    For gong-chae candidates, the next stage is typically the in-jeok-seong-geom-sa (인적성검사, personality and aptitude test). This is administered online or in person and includes a personality inventory plus cognitive sections covering language reasoning, numerical reasoning, and basic logic. Daewoong uses a test similar in format to the major Korean industry batteries (the structure is comparable to what Samsung's GSAT or SK's SKCT candidates encounter, though scored against pharma-industry norms). There is no public official prep guide; candidates use commercial Korean prep books and online practice sets to prepare.

  9. 9
    Pass the test and move to the first interview round (1차 면접), which for gong-chae

    Pass the test and move to the first interview round (1차 면접), which for gong-chae is usually a structured panel interview combining a short presentation, behavioral questions tied directly to the ja-so-seo, and competency-based scenarios. Interviews are conducted in Korean for domestic roles and in a mix of Korean and English for global business unit roles. Panels typically include the hiring manager, an HR business partner, and a senior representative from the function. Expect 45 to 90 minutes total.

  10. 10
    Advance to the final interview (임원 면접, executive interview), where one to three

    Advance to the final interview (임원 면접, executive interview), where one to three senior executives — typically including a head of division and an HR executive — assess overall fit, motivation, and long-term potential. The tone is formal and the questions are broader: career vision, alignment with Daewoong's values, willingness to relocate to manufacturing sites, and (for global roles) genuine readiness to travel and operate cross-culturally. For senior experienced hires, this round may also include a one-on-one with the CEO or a Daewoong Group-level executive.

  11. 11
    Receive a verbal offer through the recruiter, typically within one to three week

    Receive a verbal offer through the recruiter, typically within one to three weeks of the final interview. Written offers are issued through the portal and include base salary (paid in Korean won, structured as base plus performance bonus plus statutory severance accrual), benefits, start date, and any conditions tied to medical clearance or background verification. Gong-chae cohort hires have a fixed start date and join the company together for a multi-week onboarding program; experienced hires negotiate start dates individually.

  12. 12
    Complete pre-employment requirements: a health screening at a designated hospita

    Complete pre-employment requirements: a health screening at a designated hospital, submission of original academic transcripts and certifications, military service documentation for male hires, and (for relevant roles) reference verification. Onboarding for gong-chae cohorts includes intensive corporate culture training, a rotation through major business units, and assignment to a mentor (사수, sa-su) within the home team.

Resume Tips for Daewoong Pharmaceutical

recommended

Default to the Korean-language application format for any domestic-track role

Default to the Korean-language application format for any domestic-track role. The ja-so-seo essays, structured biographical fields, and certifications list are the actual evaluative documents at Daewoong, not a Western-style narrative resume. Submitting only an English CV when applying to a Korean-track role is read as either a misunderstanding of the process or a lack of seriousness about the company.

recommended

For global business unit roles, partnership-management roles, and overseas subsi

For global business unit roles, partnership-management roles, and overseas subsidiary roles, an English resume is appropriate and often preferred — but it should be paired with a short Korean cover note when possible, particularly if you are at all conversant in Korean. Daewoong's global organization works in English with U.S. (Evolus), European (Nuceiva), and Chinese (Yangtze River) partners, but reports back into a Korean-headquartered organization, so demonstrated bilingual capacity is a meaningful advantage.

recommended

Lead the ja-so-seo motivation question with a concrete, specific connection to D

Lead the ja-so-seo motivation question with a concrete, specific connection to Daewoong's actual business — Nabota's global expansion, Fexuclue's out-licensing trajectory, the CDMO buildout at Daewoong Bio, the antifibrotic pipeline, or the company's emerging-markets footprint. Generic statements about wanting to work at a Korean pharma company are immediately discounted. Candidates who can name a specific franchise and articulate why it matters to them perform measurably better.

recommended

Quantify achievements in formats that translate to a Korean reviewer

Quantify achievements in formats that translate to a Korean reviewer. Use absolute numbers, percentage improvements, and named projects rather than vague descriptors. ‘Led a 12-person team that delivered the Phase 2 readout for [program] on schedule, supporting a $40M milestone payment' is read as substantive; ‘drove cross-functional initiatives for impact' is read as filler. The same standard applies to the ja-so-seo's challenge-and-overcoming question.

recommended

List Korean national certifications (국가공인자격증) prominently

List Korean national certifications (국가공인자격증) prominently. For pharmacists, the 약사 면허 (pharmacist license) is the threshold credential for most R&D, regulatory, and certain commercial roles. For QA/QC and manufacturing, GMP-related certifications and HACCP credentials are weighted heavily. For finance and IT shared-services roles, KICPA, CFA, AICPA, and information-security certifications are common signals.

recommended

Include language scores with the official score type and date

Include language scores with the official score type and date. TOEIC and OPIc are the most commonly recognized English benchmarks in Korean corporate hiring; OPIc IH (Intermediate High) or AL (Advanced Low) and TOEIC 850+ are common thresholds for global-track roles. For Chinese-facing roles in the Yangtze River Pharma partnership orbit, an HSK score is a strong signal; for Japan-facing roles, JLPT N2 or N1.

recommended

Document military service status clearly for male applicants — completed (군필), e

Document military service status clearly for male applicants — completed (군필), exempt (면제), or scheduled (미필). This is a standard field on Korean applications and omitting it raises questions. International candidates not subject to Korean military service should leave the field blank or note their nationality.

recommended

If you have experience at a Korean conglomerate (chaebol-affiliated pharma — Han

If you have experience at a Korean conglomerate (chaebol-affiliated pharma — Hanmi, Yuhan, Chong Kun Dang, GC Cell, Samsung Biologics, Celltrion, SK Biopharmaceuticals, LG Chem Life Sciences) or at a multinational pharma's Korea subsidiary (Pfizer Korea, Merck Korea, Novartis Korea, AstraZeneca Korea, etc.), name the specific business unit and the products or therapeutic areas you supported. Daewoong's reviewers know the Korean industry intimately and read these signals precisely.

recommended

For R&D and pipeline-relevant roles, list publications in Korean Society of Phar

For R&D and pipeline-relevant roles, list publications in Korean Society of Pharmaceutical Sciences journals, KSBMB publications, and international journals (with impact factor where helpful). Patent inventorship — Korean Intellectual Property Office (KIPO) filings, PCT applications, and granted patents — is a strong signal for early-development and platform roles. Include patent numbers and a one-line description of the invention.

recommended

Tailor each ja-so-seo to the specific role and division

Tailor each ja-so-seo to the specific role and division. Daewoong's HR and hiring managers compare ja-so-seo across applicants in the same posting, and recycled essays from other companies are easy to spot — Korean reviewers commonly flag the absence of company-specific language, the presence of competitor names, and overly generic value statements. Investing the time to write a fresh ja-so-seo per application is a non-negotiable in the Korean gong-chae context.

recommended

Avoid making the Medytox litigation a centerpiece of your ja-so-seo or interview

Avoid making the Medytox litigation a centerpiece of your ja-so-seo or interview narrative. The episode is publicly resolved and operationally behind the company, and candidates who lead with it (either as a critique or as a defense) tend to read as either naive or politically tone-deaf. If the topic comes up in an interview — most likely for legal, regulatory, BD, or QA roles — engage with it factually and briefly, then pivot to the present and forward-looking strategy.

recommended

Submit documents as PDFs uploaded through the portal in the requested order

Submit documents as PDFs uploaded through the portal in the requested order. The portal accepts standard PDF, DOCX, and HWP (Hangul Word Processor) formats; HWP is acceptable for fully Korean documents but PDF is the safest universal choice. Use clean, single-column layouts with standard Korean fonts (Malgun Gothic, Nanum Gothic) for Korean documents and standard Western fonts (Calibri, Arial) for English.

ATS System: Custom Daewoong Recruiting Portal (recruit.daewoong.co.kr)

Daewoong Pharmaceutical operates a custom in-house recruiting portal at recruit.daewoong.co.kr rather than using a Western-style applicant tracking system like Greenhouse, Workday, or SuccessFactors. The portal is built and maintained internally on Korean infrastructure and follows the conventions of large Korean conglomerate recruiting systems: a structured account with persistent profile data, a multi-step application form per requisition, integrated ja-so-seo essay submission with character-count enforcement, in-portal status tracking through each stage of the hiring funnel, and SMS notifications routed to a Korean mobile number. The portal supports both Korean and English language interfaces, but the underlying data model and most communication defaults to Korean. Application history persists across recruiting cycles, and re-applying to a new gong-chae or experienced-hire posting reuses the same account.

  • Verify your Korean mobile number at account creation. The portal uses SMS for nearly all real-time notifications — document screen results, interview invitations, test scheduling, and offer status — and many candidates miss critical updates because they registered an outdated or international number that the system silently fails to deliver to. International candidates without a Korean number should contact the recruiting team directly via the contact form to confirm an alternate notification channel.
  • Save your ja-so-seo essays as plain text outside the portal as you write them. The portal's session timeout and occasional outages have a long history of erasing in-progress essays, and the consequence of losing a 1,000-character Korean ja-so-seo at 11:30pm on the deadline night is severe. Draft offline, paste in cleanly, and submit early.
  • Stay under the published character limits exactly. Each ja-so-seo question shows a character counter and hard-truncates at the limit — your answer is silently cut off mid-sentence if you exceed. Korean character counts are typically counted by 자수 (character count, including spaces unless otherwise specified), and what looks like ‘a few characters over' in a Western mental model can clip the conclusion of your essay.
  • Upload supporting documents in the requested order and naming convention. The portal expects specific filenames or document categories for transcripts, certifications, and portfolios. Mislabeled documents are sometimes treated as missing, and the document-screening reviewers do not chase candidates for re-uploads in the gong-chae context.
  • Apply only once per requisition per cycle. The portal deduplicates by your account ID, and submitting twice for the same role does not create a fresh review — it overwrites or queues the second submission depending on portal version, with unpredictable downstream behavior. If you need to update a submission, withdraw the original cleanly through the portal interface (where supported) before resubmitting.
  • Do not rely on Western browser autofill for Korean-language fields. Names, addresses, and organization names should be entered manually using a Korean IME (Input Method Editor) to ensure correct Hangul rendering. Romanized or auto-corrected Korean names in your registered profile cause downstream issues with offer paperwork and HRIS provisioning.
  • For overseas-subsidiary roles, check whether the posting is hosted on the global recruit.daewoong.co.kr portal or routed through a country-specific channel (LinkedIn for U.S. roles, local job boards for China, Indonesia, Vietnam, India). Some overseas roles are managed entirely outside the Seoul HQ portal, and applying through the wrong channel can route your application to a queue that is not actively reviewed.

Interview Culture

Daewoong's interview culture is recognizably Korean big-pharma: formal, hierarchical in framing but increasingly substantive in content, and structured to evaluate both individual capability and fit with a long-tenured organization. Candidates should plan for a process that takes their formal Korean business communication, Confucian-rooted respect cues, and ja-so-seo-derived narratives as seriously as their technical answers. Bowing on entry to the interview room, addressing interviewers with appropriate honorifics (전무님, 상무님, 부장님, depending on rank), and waiting to be seated are still the default expectations. Western informality reads as either inexperience or disrespect. The first-round interview for gong-chae candidates is a structured panel that combines a short self-introduction (자기소개), follow-up questions tied directly to the ja-so-seo essays, behavioral and competency-based scenarios, and (for many roles) a brief case or PT (presentation) component. The PT is typically 5 to 10 minutes on a topic chosen from a shortlist provided 30 to 60 minutes before the interview, presented to the panel without slides or with a single hand-drawn whiteboard. Panels are 3 to 5 interviewers, almost always include an HR representative, and ask candidates to expand on the specific examples written in their ja-so-seo — fabricating examples is fatal, because the panel can and will ask you to walk through the underlying detail. For experienced-hire candidates, the first round is more conventional: a hiring manager and one or two senior teammates probing technical depth, prior project ownership, and the specifics of your domain experience. The final interview (임원 면접) is conducted by 1 to 3 executives — typically including the head of the relevant division, an HR executive, and for senior roles a board-adjacent figure. The tone is formal and the questions are deliberately broader: career vision, alignment with Daewoong's values (생명존중 respect for life, 정직 integrity, 도전 challenge), reaction to hypothetical strategic dilemmas, and willingness to commit to long-tenure trajectories that include possible relocation to Hyangnam, Osong, or overseas. For global business unit and overseas-subsidiary roles, this round routinely includes English-language sections to validate language proficiency in real working conditions, often with a brief impromptu discussion of a recent industry development or a Daewoong-related news item. Daewoong's evaluative emphasis differs by track. For R&D, the panel will probe scientific depth, methodology choices, and the candidate's ability to articulate experimental rationale and limitations honestly — Korean pharma R&D leaders are increasingly trained at major international academic and industry institutions and the technical bar at the second round is genuinely high. For commercial and sales roles, panels focus on relationship management, KOL (key opinion leader) familiarity within the relevant therapeutic area, and the ability to navigate hospital and pharmacy stakeholders inside the Korean healthcare system's specific reimbursement and procurement dynamics. For global business and out-licensing roles, panels weigh deal experience, partner-management posture, and the ability to operate across the U.S.–Europe–China–Korea time zone and cultural matrix that defines Daewoong's global footprint. For QA, regulatory, and manufacturing roles, the bar is built around demonstrated experience under K-GMP, US FDA, EMA, and PMDA frameworks, with rigorous probing of audit history and CAPA discipline. The Medytox litigation is handled in interviews with a posture of resolved professionalism. For most roles it does not come up at all; for legal, regulatory, BD, and QA roles it may be raised as a way of testing the candidate's awareness of public industry events and their judgment in discussing sensitive corporate matters. The right approach is to acknowledge the public record briefly and factually, signal an understanding that the matter is settled and operationally behind the company, and move the conversation toward present and forward-looking work. Candidates who attempt to litigate the case in the interview, or who feign ignorance of obviously public information, both perform poorly. Feedback timelines after each round are typically one to three weeks for gong-chae cohorts (synchronized to the cohort calendar) and one to two weeks for experienced-hire roles. The full process from application to offer typically runs eight to twelve weeks for gong-chae and four to eight weeks for experienced-hire, with global-track roles occasionally extending due to overseas executive availability. Compensation discussions are direct but conducted later in the process than at U.S. companies — typically only after the final interview and verbal selection — and are anchored to published Korean pharma industry bands rather than individual negotiation, with senior experienced-hire roles being the main exception.

What Daewoong Pharmaceutical Looks For

  • Demonstrated commitment to a long-tenure career path. Daewoong, like most Korean conglomerate-affiliated pharma, screens hard for candidates who present a coherent multi-year career narrative rather than short-tenure job-hopping. Two-year stints with no clear explanatory arc read as a risk, particularly for gong-chae roles where the company is investing in a multi-year development trajectory. Candidates who can articulate why Daewoong fits a 5-to-10-year horizon perform meaningfully better.
  • Genuine alignment with Daewoong's stated values. The 생명존중 (respect for life), 정직 (integrity), and 도전 (challenge) framing is not boilerplate inside the company — it shows up in interviews, performance reviews, and internal communications. Candidates who can connect their own examples to these values without sounding rehearsed perform well; candidates who treat the values as a checklist exercise are visibly downgraded.
  • Specific, current knowledge of Daewoong's franchises. Interviewers expect candidates to know the basics of Nabota's global footprint (Evolus/Jeuveau in the U.S., Nuceiva in Europe and Canada), Fexuclue's strategic positioning as a P-CAB and the Yangtze River Pharmaceutical China partnership, and the Daewoong Bio CDMO story. Candidates who can also speak to Hanall Biopharma's relationship to the group, or to recent earnings commentary, signal serious preparation.
  • Bilingual capability for global-track roles. Genuine Korean–English working bilingualism is a baseline expectation for the global business unit, the out-licensing organization, and any role with regular partner interaction. Candidates who can demonstrate this in real-time during the interview — switching between languages naturally to discuss a deal structure or a regulatory point — are sharply differentiated from candidates whose English is purely test-score-validated.
  • Domain depth tied to Daewoong's actual pipeline. For R&D and clinical roles, the company prefers candidates with hands-on experience in metabolic disease, autoimmune indications, antifibrotics, oncology (specifically the modalities Daewoong is developing), or P-CAB and acid-suppression mechanism work. Generic ‘medical research' framing underperforms; specific therapeutic-area and modality expertise overperforms.
  • Regulated-environment fluency for QA, regulatory, and manufacturing roles. Daewoong evaluates candidates against K-GMP and increasingly against US FDA, EMA, and PMDA standards. Audit experience, CAPA leadership, and product-tech-transfer ownership are weighted heavily. Candidates who have actually delivered approvals or led audit responses (rather than supported them) consistently advance.
  • Cultural readiness for a hierarchical organization. Daewoong is modernizing but remains a Korean conglomerate-adjacent company with a structured rank ladder (사원 → 대리 → 과장 → 차장 → 부장 → 임원 line for shared services; with parallel structures in R&D and commercial). Candidates who have only worked in flat Western tech-style organizations sometimes struggle with the formal communication norms; the company looks for evidence that candidates can operate effectively within that structure without losing their ability to push ideas.
  • Mobility and willingness to base where the work is. Most R&D and corporate roles are Seoul-based; manufacturing and quality roles are based in Hyangnam (Hwaseong) and Osong; CDMO roles route through Daewoong Bio's facilities. Global business roles may require frequent travel to the U.S., Europe, China, and Southeast Asia. Candidates who treat location as a deal-breaker negotiable late in the process tend to stall in the final interview.
  • Ja-so-seo authenticity. The Korean-language ja-so-seo essays are read carefully and cross-referenced against the interview answers. Candidates whose interview narratives diverge from their written essays — or who clearly used a generic essay across multiple companies — are flagged immediately. Authenticity, specificity, and consistency between written and spoken accounts is one of the highest-leverage things a candidate can deliver.
  • Comfort discussing the Medytox episode briefly and professionally for relevant roles. For legal, regulatory, BD, QA, and senior leadership candidates, the ability to engage with the public record on the litigation matter — acknowledging it factually, treating it as resolved, and pivoting forward — is a small but real differentiator. Candidates who panic, deflect, or attempt to either over-defend or over-criticize the company's conduct underperform.

Frequently Asked Questions

What ATS does Daewoong Pharmaceutical use to manage applications?
Daewoong runs a custom in-house recruiting portal at recruit.daewoong.co.kr rather than a Western applicant tracking system. The portal supports Korean and English interfaces, requires a Korean mobile number for full notification functionality, and persists candidate accounts across recruiting cycles. All gong-chae and most experienced-hire applications route through this portal; some overseas-subsidiary roles are posted on local channels like LinkedIn or country-specific job boards.
When are Daewoong's gong-chae (new-graduate cohort) cycles?
Daewoong runs at least one major shin-ip gong-chae cohort per year, typically in the second half of the calendar year, with a smaller secondary intake in some years. Exact dates are published on the recruit.daewoong.co.kr portal and announced through major Korean job-search platforms. The full process from application deadline to start date typically spans three to four months and culminates in a synchronized cohort start date and multi-week onboarding program.
Do I need to write the ja-so-seo (자기소개서) in Korean?
For domestic Korea-based roles in the gong-chae and experienced-hire tracks, yes — the ja-so-seo is written in Korean and evaluated by Korean-speaking reviewers. For roles in the global business unit, certain partnership-management positions, and overseas subsidiaries, English ja-so-seo or hybrid Korean-English applications are accepted; check the specific job posting for the language requirement. Submitting an English-only application for a Korean-track role is read as a misunderstanding of the process.
Is the Medytox litigation still a concern for candidates?
The Medytox dispute over the Nabota botulinum toxin strain provenance was substantially resolved in 2021 through a settlement involving Daewoong's U.S. partner Evolus, with a reported payment in the range of $13.5 million plus ongoing royalty arrangements. Remaining ancillary matters wound down through 2024. The episode is publicly documented and operationally behind the company. For most roles it will not come up in interviews; for legal, regulatory, BD, and QA roles, the topic may be raised as a way of testing your awareness and judgment, and the right approach is to acknowledge the public record briefly and factually before pivoting forward.
Does Daewoong sponsor work visas for international hires?
Daewoong sponsors Korean work visas (typically E-7 for specialty professionals and E-3 for researchers) for international hires in roles where the talent pool is genuinely global — particularly senior R&D, global business unit, and specialized partnership management positions. Sponsorship is less common for gong-chae cohort hires, which are oriented primarily toward Korean and Korean-fluent candidates, and for domestic commercial roles. Timelines for E-7 visa processing typically run four to eight weeks after offer acceptance.
What is the in-jeok-seong-geom-sa (인적성검사) aptitude test like?
The in-jeok-seong-geom-sa is a Korean-style personality and cognitive aptitude test administered after the document screen for most gong-chae cohorts. The test includes a personality inventory plus cognitive sections covering language reasoning, numerical reasoning, and basic logic, with a structure broadly comparable to the major Korean industry batteries used by Samsung (GSAT), SK (SKCT), and others, though scored against pharma-industry norms. There is no public official prep guide; candidates typically prepare with commercial Korean test-prep books and online practice sets in the four to six weeks between document-screen results and the test date.
What's the difference between Daewoong Pharmaceutical, Daewoong Co., Daewoong Bio, and Hanall Biopharma?
Daewoong Co., Ltd. is the holding company at the top of the group structure. Daewoong Pharmaceutical Co., Ltd. (KOSPI: 069620) is the listed operating company that owns the Nabota, Fexuclue, and Anpec franchises and is the entity most candidates apply to. Daewoong Bio is the CDMO and active pharmaceutical ingredient arm of the group, operating from a separate manufacturing footprint. Hanall Biopharma (Kosdaq-listed) is a separate biotech company in which the Daewoong group holds a meaningful minority position; it operates with its own management and pipeline but is widely understood as a Daewoong-affiliated entity. Career mobility across these entities exists but is not automatic — each has its own hiring process and HRIS.
How does Daewoong compare to Hanmi, Yuhan, Chong Kun Dang, and the other top Korean pharmas?
Daewoong sits in the same top tier as Hanmi Pharmaceutical, Yuhan Corporation, Chong Kun Dang, GC Cell (formerly Green Cross), and (in biologics) Samsung Biologics and Celltrion. Daewoong differentiates on its global Nabota franchise (genuinely revenue-meaningful in the U.S. and Europe via Evolus and Nuceiva), the Fexuclue out-licensing strategy that puts it in the small group of Korean pharma originators with a globally relevant new molecular entity, and the Daewoong Bio CDMO arm. Lateral movement among these companies is common at the experienced-hire level and well understood by interviewers; candidates should be prepared to articulate clearly why Daewoong specifically fits their next move.
Are most roles based in Seoul, or in the manufacturing sites?
Headquarters and most R&D, commercial, finance, IT, HR, legal, and global business unit roles are based in Seoul. Manufacturing, quality, and certain technical R&D roles are based at the Hyangnam (Hwaseong) and Osong sites. CDMO roles route through Daewoong Bio's facilities, which have their own footprint. Overseas subsidiary roles are based in the relevant country (United States, China, Indonesia, Vietnam, India, and others). Daewoong is candid about location requirements in its postings, and candidates who are not flexible on location should focus their applications accordingly.
What is the compensation structure at Daewoong?
Compensation is paid in Korean won and structured as a base salary, a performance bonus tied to company and individual results, statutory severance accrual (퇴직금), and standard Korean benefits including national health insurance, national pension, employment insurance, workers' compensation, and Daewoong-specific welfare programs (family medical support, education subsidies, employee discount on Daewoong products, on-site cafeteria, group life insurance). For gong-chae cohort hires, compensation is anchored to published industry bands with limited individual negotiation; for senior experienced hires and global business roles, individual negotiation is more common and is conducted late in the process after the final interview.
Can I apply if I do not speak Korean?
For roles in the global business unit, partnership-management functions, certain R&D positions in international collaborations, and overseas subsidiaries, yes — the role and its application channel will typically be marked as English-eligible. For the vast majority of HQ-based roles in the Korean gong-chae and experienced-hire tracks, functional Korean is a practical requirement, even if the role nominally accepts English applications, because the working language of the team and the supporting infrastructure is Korean. Candidates without Korean should focus their search on global, overseas-subsidiary, and partnership-facing roles, and consider whether a Korean-language commitment fits their longer-term career plan if they want to grow inside Daewoong.
What does Fexuclue's global out-licensing mean for hiring?
Fexuclue (fexuprazan), Daewoong's in-house P-CAB for GERD and related acid-suppression indications, is the company's strategic bet on becoming a globally relevant Korean pharma originator. It launched in Korea in 2022 and reached the Chinese market in 2024 through a major partnership with Yangtze River Pharmaceutical. The company is actively pursuing additional out-licensing deals across Southeast Asia, the Middle East, Latin America, and other emerging markets. From a hiring perspective, this drives strong demand for global business development professionals, regulatory specialists with multi-jurisdiction experience, medical affairs and clinical operations leaders capable of supporting registration trials in partner markets, and supply chain professionals who can manage international product flow.

Open Positions

Daewoong Pharmaceutical currently has 6 open positions.

Check Your Resume Before Applying → View 6 open positions at Daewoong Pharmaceutical

Related Resources

Similar Companies

Related Articles